Gain Therapeutics SA Announces Jeffrey Riley to join its Board of Directors
Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in CNS diseases, today announced that Mr. Jeffrey Riley joined Gain Therapeutics as Independent Board Member.
Mr. Riley has more than 25 years of experience in the biotechnology and pharmaceutical industries, during which he has negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in venture financings to support product development. He has raised over $1.5B in equity and debt instruments. He has worked for big pharma (SmithKline Beecham and Pfizer), venture capital (Queensland Biocapital Fund / QIC) and numerous biotechnology companies in his capacity of business development and general management.
“We are delighted to have Jeff join us as an independent board member,” said Dr. Khalid Islam, Chairman of the Board of Gain Therapeutics SA. “Jeff’s perspective, based on his distinguished career and leadership roles in R&D organizations and his transactional expertise will be very valuable to the board as the company seeks to execute on its global product discovery and development strategy."
“I am delighted to join Gain Therapeutics and support its endeavors to bring to patients brain penetrant small molecule able to regulate misfolded enzymes involved in rare pediatric diseases and in neurodegenerative disease for which high unmet medical needs still exist.” Said Mr. Jeffrey Riley, Independent Board member of Gain Therapeutics.
About Gain Therapeutics SA
Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NY-THIRD-POINT24.2.2020 18:35:05 CET | Press release
Third Point Sends Letter to Prudential plc Highlighting Opportunity to Separate US and Asian Businesses
MN-CALABRIO24.2.2020 18:22:05 CET | Press release
Calabrio Named a Visionary in Gartner Magic Quadrant for Workforce Engagement Management for Fourth Year Running
CA-VERIMATRIX24.2.2020 17:42:14 CET | Press release
Albania’s Largest Video Service Provider TiBO Deploys Verimatrix Multi-DRM For Cloud-based Digital Rights Management
NC-BIOVENTUS24.2.2020 16:02:11 CET | Press release
Bioventus Recognizes 25 Years of Proven Bone Healing from EXOGEN
GIGABYTE24.2.2020 16:02:10 CET | Press release
MWC Canceled, GIGABYTE Turns Its Exhibition Digital and Showcases Multi-access Edge Computing Infrastructure to Realize 5G Networks
BACARDI-LIMITED24.2.2020 14:32:06 CET | Press release
Bacardi Names Industry Veteran Kathy Parker Chief Marketing Officer for PATRÓN® tequila and GREY GOOSE® vodka
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom